SAB Biotherapeutics, Inc.
SABS
$3.70
-$0.05-1.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -122.37% | -263.09% | -47.97% | 539.11% | -37.88% |
| Total Depreciation and Amortization | 7.83% | -3.29% | -2.85% | -20.83% | -26.68% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 588.45% | 232.91% | 115.34% | -6,223.37% | 173.21% |
| Change in Net Operating Assets | 244.04% | -293.57% | -288.28% | -22.54% | 257.96% |
| Cash from Operations | -37.58% | -83.03% | -76.00% | -107.41% | 7.32% |
| Capital Expenditure | -- | -- | -1,584.48% | -- | -- |
| Sale of Property, Plant, and Equipment | 60.00% | 340.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -163.46% | -1,484.55% | -108.24% | -12,241.43% | -53.89% |
| Cash from Investing | -193.95% | -1,505.40% | -118.29% | -11,167.47% | -53.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 77.83% | 78.24% | 86.61% | 94.45% | 30.99% |
| Issuance of Common Stock | 2,406,800.00% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -119.05% | 82.73% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,458.56% | 51,778.79% | -119.22% | 25,124.33% | 45.79% |
| Foreign Exchange rate Adjustments | -40.22% | -65.41% | -37.82% | -178.95% | 534.28% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -528.55% | 407.50% | -6,826.06% | 418.81% | -160.76% |